Most Recent
Viterra has failed in its third bid to access communications between Cargill Australia and its lawyers related to Cargill's $420 million purchase of malt producer Joe White Maltings from Viterra in 2013.
Optus was ordered Wednesday to temporarily pull an ad that Telstra alleges makes a false and damaging claim about the superiority of Optus' mobile network.
The financing arrangement underwriting Quinn Emanuel's shareholder class action against AMP, which will earn its partner Burford Capital a record low 10 percent of any recovery, sets a new standard in class action litigation funding, and is expected to spark greater price competition in the industry.
Drug giant F. Hoffman-La Roche asked the Federal Court Tuesday for an order barring the release of a generic version of its blockbuster cancer drug MabThera by a unit of Swiss rival Novartis, which it claims could lead to "tens of millions of dollars" in losses.
The long awaited second phase in the Australian Competition and Consumer Commission's cartel proceedings against Air New Zealand has been set down for June 27, one year after the High Court ruled the airline had breached Australia's competition law.
AMP's chairwoman Catherine Brennar has resigned and the firm's general counsel has left, as the company faces possible criminal charges for misleading the corporate regulator over its decade-long practice of charging undue fees to clients.
Cargill has won a discovery dispute in a case alleging fraudulent concealment by Viterra in its $420 million sale of malt producer Joe White Maltings to Cargill Australia in 2013, with a judge finding documents attached to privileged emails or emails that are part of a privileged chain are protected by legal professional privilege.
AMP's chief executive Craig Meller has resigned after this week's shocking revelations that the company misled ASIC over fees charged to customers and may have influenced a Clayton Utz report to the securities regulator.
A lawyer for the University of Sydney has attacked ObjectiVision for failing to produce any commercial benefits from the glaucoma detection method at the centre of a patent infringement dispute, despite holding exclusive rights to the technology for 11 years.
Expert witnesses were pitted against each other Wednesday at a trial alleging generic makers infringed a patent covering the anti-depressant Lexapro, and Apotex' consultant took the brunt of it.